Dashboard
Manage Tickers

SABS


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
10/03/2025 21:05:59

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/30/2025 21:06:48

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 21:07:00

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
09/19/2025 21:06:05

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
09/19/2025 17:06:19

chardan-capital-maintains-buy-on-sab-biotherapeutics-maintains-12-price-target
Chardan Capital Maintains Buy on SAB Bioth...
09/19/2025 15:59:31

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.

sab-biotherapeutics-showcases-sab-142-data-at-easd-phase-2b-safeguard-study-in-new-onset-stage-3-t1d-underway-innodia-meld-atg-results-further-validate-disease-modifying-potential
SAB Biotherapeutics Showcases SAB-142 Data...
09/19/2025 11:28:35

leerink-partners-initiates-coverage-on-sab-biotherapeutics-with-outperform-rating-announces-price-target-of-7
Leerink Partners Initiates Coverage On SAB...
09/17/2025 12:20:08

Leerink Partners initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Outperform rating and announces Price Target ...

sab-biotherapeutics-to-present-at-the-61st-annual-meeting-of-the-european-association-for-the-study-of-diabetes-easd-being-held-september-15--19-2025-at-the-viecon---vienna-congress--convention-center-in-vienna-austria
SAB Biotherapeutics To Present At The 61st...
09/03/2025 20:18:36

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB BIO" or the "Company"...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/03/2025 12:08:15

chardan-capital-maintains-buy-on-sab-biotherapeutics-lowers-price-target-to-12
Chardan Capital Maintains Buy on SAB Bioth...
08/08/2025 12:02:41

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $...

sab-biotherapeutics-q2-eps-109-misses-049-estimate
SAB Biotherapeutics Q2 EPS $(1.09) Misses ...
08/07/2025 11:54:06

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/23/2025 12:08:15

hc-wainwright--co-maintains-buy-on-sab-biotherapeutics-lowers-price-target-to-9
HC Wainwright & Co. Maintains Buy on SAB B...
07/22/2025 10:21:19

HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price tar...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
07/21/2025 12:08:15

sab-bio-raises-175m-in-oversubscribed-private-placement-to-fully-fund-phase-2b-safeguard-trial-for-autoimmune-type-1-diabetes
SAB BIO Raises $175M In Oversubscribed Pri...
07/21/2025 11:36:39

Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, ...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/29/2025 21:06:36

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/21/2025 21:06:07

chardan-capital-maintains-buy-on-sab-biotherapeutics-maintains-20-price-target
Chardan Capital Maintains Buy on SAB Bioth...
05/15/2025 15:31:33

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $20 price target.

hc-wainwright--co-assumes-sab-biotherapeutics-at-buy-announces-price-target-of-10
HC Wainwright & Co. Assumes SAB Biotherape...
05/14/2025 16:56:58

HC Wainwright & Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION